Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis
- PMID: 11343046
- DOI: 10.1067/mpd.2001.112897
Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis
Abstract
Objective: To determine the clinical consequences of acquiring Pseudomonas aeruginosa infection during early childhood in children with cystic fibrosis (CF).
Design: Prospective, observational cohort study of 56 children with CF identified by newborn screening during 1990-92. Each child underwent an annual bronchial lavage during the first 2 to 3 years of life. Clinical outcome was determined at 7 years of age.
Results: P aeruginosa infection was diagnosed in 24 (43%) cohort subjects. Four children died before 7 years of age, all of whom had been infected with a multi-resistant, mucoid strain of P aeruginosa (P =.04). In survivors, P aeruginosa infection was associated with significantly increased morbidity as measured by lower National Institutes of Health scores, greater variability in lung function, increased time in the hospital, and higher rates of recombinant human deoxyribonuclease therapy (P <.01). In this young CF cohort, best forced expiratory volume in 1 second was an insensitive measure of increased morbidity.
Conclusions: Acquisition of P aeruginosa was common by 7 years of age in this CF birth cohort and was associated with increased morbidity and mortality. An improved disease severity score would improve the evaluation and study of early CF lung disease.
Similar articles
-
Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.Pediatr Pulmonol. 2002 Aug;34(2):91-100. doi: 10.1002/ppul.10127. Pediatr Pulmonol. 2002. PMID: 12112774
-
Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic pseudomonas aeruginosa infections, and dornase alfa use.J Pediatr. 2008 Dec;153(6):752-7. doi: 10.1016/j.jpeds.2008.07.011. Epub 2008 Aug 29. J Pediatr. 2008. PMID: 18760423
-
Cystic fibrosis diagnosed after 2 months of age leads to worse outcomes and requires more therapy.Pediatrics. 2007 Jan;119(1):19-28. doi: 10.1542/peds.2006-1498. Pediatrics. 2007. PMID: 17200267
-
Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.APMIS Suppl. 2003;(116):1-47. APMIS Suppl. 2003. PMID: 14692154 Review.
-
Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.Expert Opin Pharmacother. 2010 Jun;11(8):1373-85. doi: 10.1517/14656566.2010.482102. Expert Opin Pharmacother. 2010. PMID: 20426707 Review.
Cited by
-
The Evolution of Cystic Fibrosis Care.Chest. 2015 Aug;148(2):533-542. doi: 10.1378/chest.14-1997. Chest. 2015. PMID: 25764168 Free PMC article. Review.
-
Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR.PLoS One. 2011;6(9):e23637. doi: 10.1371/journal.pone.0023637. Epub 2011 Sep 1. PLoS One. 2011. PMID: 21909403 Free PMC article.
-
Microbial Interactions in the Cystic Fibrosis Airway.J Clin Microbiol. 2018 Jul 26;56(8):e00354-18. doi: 10.1128/JCM.00354-18. Print 2018 Aug. J Clin Microbiol. 2018. PMID: 29769279 Free PMC article.
-
The Pseudomonas aeruginosa AlgZR two-component system coordinates multiple phenotypes.Front Cell Infect Microbiol. 2014 Jun 20;4:82. doi: 10.3389/fcimb.2014.00082. eCollection 2014. Front Cell Infect Microbiol. 2014. PMID: 24999454 Free PMC article. Review.
-
Polymicrobial Interactions in the Cystic Fibrosis Airway Microbiome Impact the Antimicrobial Susceptibility of Pseudomonas aeruginosa.Antibiotics (Basel). 2021 Jul 7;10(7):827. doi: 10.3390/antibiotics10070827. Antibiotics (Basel). 2021. PMID: 34356747 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical